Shanghai Reopens, Beijing Offers Policy Relief As Pharma Embraces Uncertain Future
COVID Situation Still Fluid
Executive Summary
China’s largest commercial center and pharma industry hub reopens after over two months of strict lockdown.
You may also be interested in...
COVID Unrest, Health Sector Deep Freeze Hits Chinese Biotechs Hard
Much of the biopharma and other health-related industries in China were already feeling the chill from ongoing macro-economic and other headwinds this year, which now look set to be complicated further by the added strain of social unrest over strict COVID containment policies. The combination of factors is already prompting some to take steps towards restructuring and divestments to survive.
China Walks Back Some Relaxations Amid New COVID Outbreaks
With growing cases and deaths reported just as the country was preparing to ease some of its most restrictive COVID-19 measures, China takes new control steps amid low booster vaccine uptake and moves to halt the online sale of a repurposed domestic antiviral.
Biotech CEO Interview: Harbour BioMed's Wang On Moderna Deal, New Subsidiary
After inking major deals with AbbVie and AstraZeneca, China-US company Harbour BioMed recently shifted strategy, divesting its site in Suzhou to WuXi in a bid to be “more focused, efficient and nimble” and emerge stronger post-pandemic, says founder, chairman and CEO Jingsong Wang in an exclusive interview.